Otsuka reports confirmatory VISIONARY data for Voyxact in IgAN

CURRENT BRIEF VERSION: Otsuka said new Phase 3 VISIONARY data for Voyxact (sibeprenlimab-szsi) in IgA nephropathy showed the drug slowed kidney function decline, adding confirmatory evidence beyond the proteinuria reduction that supported its November 2025 FDA accelerated approval. The company had already disclosed that Voyxact won approval to reduce proteinuria in adults with primary IgA nephropathy at risk for progression, with continued approval tied to verification of clinical benefit from the ongoing VISIONARY study. ClinicalTrials.gov lists VISIONARY as a randomized, placebo-controlled Phase 3 study that enrolled 530 patients and is evaluating eGFR change over roughly 24 months as a key secondary endpoint. The update also comes as Otsuka is making broader pipeline moves, including an agreement through Otsuka America to acquire Transcend Therapeutics for about $1.225 billion upfront and milestones, a deal aimed at expanding its psychiatric and neurology portfolio and expected to close in Q2 2026. (otsuka.co.jp)

Why it matters: For veterinary professionals tracking translational kidney research, this is another sign that mechanism-based therapies aimed at upstream immune drivers are moving beyond surrogate markers and toward harder renal outcomes. Voyxact targets APRIL and is designed to reduce production of galactose-deficient IgA1, a key disease driver in IgA nephropathy; that differentiates it from other approved or late-stage IgAN drugs such as sparsentan, atrasentan, and targeted-release budesonide, which act through different pathways. The company context is also worth noting: while Voyxact advances in nephrology, Otsuka is simultaneously deploying capital elsewhere, with the planned Transcend buy adding TSND-201 (methylone), a Phase 3 PTSD candidate, to its CNS pipeline. In human nephrology, confirmatory eGFR data are what will shape traditional approval, guideline placement, and long-term treatment sequencing, so the VISIONARY readout matters well beyond a single brand. (accessdata.fda.gov)

What to watch: Watch for the full dataset, including exact eGFR effect size, safety details, and any regulatory update on conversion from accelerated to traditional approval, plus how Voyxact is positioned against other IgAN therapies already on the market or advancing toward approval. At the company level, Otsuka’s expected Q2 2026 close of the Transcend acquisition may offer another read on how aggressively it is balancing renal and CNS growth bets. (businesswire.com)